Project Grant 2528222
Award Date 10/1/25
Completion Date 9/30/26
Dollars Obligated $305K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- This SBIR Phase I grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $303,864 to Core Biotherapeutics, Inc. to develop a platform for discovering disruptive drug candidates that can address high unmet medical needs. The project aims to determine the biological laws of molecular networks driving diseases and program these into an efficient, scalable algorithm for drug target discovery. The goal is to enable the rapid design and...
- Biomesense Inc. received a $255,658 National Science Foundation SBIR Phase I Project Grant to develop a novel biosensor to accelerate investigations of COVID-19 and the gut microbiome. Funded under the NSF Engineering program (CFDA 47.041), this six-month award beginning January 15, 2021 supports the company's work to design a portable, low-cost biosensor device capable of rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition directly from patient samples. The NSF Directorate for...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) SBIR Phase I Project Grant award of $305,000.00 to Absco Therapeutics, Inc. aims to develop an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors, a $125 billion market. The project seeks to create an innovative drug delivery platform that can improve the efficacy and reduce the toxicity of biological cancer therapies by enhancing on-target delivery and controlling...
- The National Science Foundation (NSF) awarded a $305,000 Small Business Innovation Research (SBIR) Phase I project grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Primary Bioscience, Inc. The project aims to develop an ultra-sensitive biosensor capable of protein analysis at the single-molecule level. The biosensor utilizes a nanopatterned chip with a proprietary scaffold material to bind and immobilize molecular targets, which are then detected using...
- The National Science Foundation (NSF) awarded a $305,000 Small Business Innovation Research (SBIR) Phase I grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Novaurum Biosciences Incorporated in Somerville, MA. The project aims to develop a novel mammalian cell-based nano-biological coating for implantable medical devices that can inhibit biofilm formation and protect against bacterial infections, including antibiotic-resistant strains, while promoting...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project aims to advance infectious disease research and diagnostics through improved genetic sequencing. The $304,995 award, granted on June 1, 2025, will fund the development of the Host-Pathogen Enrichment Platform (HOSTPATHEP), which will produce infection-specific reagent products to enhance the sensitivity and specificity of RNA sequencing assays in...
- The National Science Foundation (NSF) awarded a Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Femtofluidics Incorporated for $294,932 on January 1, 2025. The purpose of this SBIR Phase I award is to develop hardware that enables the rapid and inexpensive synthesis of DNA-encoded libraries (DELs). This technology aims to accelerate drug discovery by expediting the identification of drug candidates for challenging diseases and generating data to...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- The National Science Foundation (NSF) awarded a $274,362 SBIR Phase I Project Grant to RT Microdx Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant funds the development of a novel molecular diagnostic platform for detecting respiratory diseases, including strep throat, that can be used at home without an expensive tabletop device. The platform leverages a combination of isothermal amplification and pH-sensitive polymers to detect specific bacterial DNA...
- This $275,000 SBIR Phase I Project Grant awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program aims to develop a high-throughput platform for small molecule targeting of undruggable proteins via their mRNAs. The project seeks to create an efficient and cost-effective approach for developing therapeutics for previously undruggable diseases, including neurodegenerative diseases and aggressive cancers. The proposed...